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  Background.   Respiratory failure in acute organophosphate (OP) poisoning can occur early and also relatively late in the clinical course, 
and the pathophysiology of respiratory failure at these different phases may have important clinical implications.   Objective.   To  compare 
the electrophysiological fi  ndings in patients with early and late respiratory failure following acute OP poisoning.   Methods.   A  prospective 
observational case series of consenting symptomatic patients with acute OP poisoning were assessed with daily physical examinations 
and repetitive nerve stimulation (RNS) studies. RNS was done on right and left median and ulnar nerves at 1, 3, 10, 15, 20, and 30 Hz. 
Outcomes such as need for ventilation and development of intermediate syndrome (IMS) were noted. Early respiratory failure was defi  ned 
as occurring within 24 hours of ingestion.   Results.   Seventy-eight patients were recruited for the clinical and electrophysiological study 
and of those 59 (75.6%) patients had ingested chlorpyrifos. Seven patients developed respiratory failure within 24 hours of ingestion 
with overt muscarinic signs. They had no electrophysiological abnormalities at median and ulnar nerves before intubation. Three of them 
later developed   “  forme fruste  ”   IMS. Five other patients developed late respiratory failure after 24 hours of ingestion, and all of them 
showed progressive RNS changes indicating severe IMS prior to intubation.   Conclusion.   The normal RNS in all patients developing early 
respiratory failure suggests that it is due to a central nervous system (CNS) and muscarinic effect. This emphasizes the need for early rapid 
atropinisation as a priority, combating the nicotinic effects being less urgent. This is in contrast with the late respiratory failure, which has 
been shown to be associated with neuromuscular dysfunction. Further studies are needed to quantify CNS and muscarinic dysfunction to 
assist in the development of better treatments for the severe and early OP poisoning.   
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  Background 
  Acute organophosphate (OP) poisoning is a major global 
health problem  1,2  with hundreds of thousands of deaths every 
year.  3,4   Respiratory failure is a signifi  cant cause of the high 
morbidity and mortality from acute OP poisoning, especially 
in resource poor settings in developing countries. 
  Respiratory failure occurs with two relatively distinc-
tive clinical patterns. An early form occurs at or soon after 
admission in patients with impaired level of consciousness 
and with marked muscarinic features.  5   Late respiratory fail-
ure typically occurs in conscious patients whose muscarinic 
symptoms are controlled and is attributed to weakness of the 
respiratory muscles due to intermediate syndrome (IMS).  6,7  
There are many potential mechanisms of respiratory failure 
following acute OP poisoning. Animal studies support the 
idea that early OP-induced respiratory failure results from 
effects of OPs on muscarinic brainstem circuits, thereby 
interfering with respiratory rhythmogenesis, and on lung tis-
sues thereby affecting secretary, airway, and vascular func-
tion.  8   The main objective of this study was to compare the 
electrophysiological fi  ndings associated with early and late 
respiratory failure in humans.     
 Methods 
  A prospective observational study of symptomatic OP poi-
soned patients was carried out in the Central Province of 
Sri Lanka with the approval of the Ethics Committees of 
the University of Peradeniya, Sri Lanka and the Australian 
National University, Canberra, Australia. Patients were 
recruited from General Hospital, Nuwara Eliya from May 
Clinical Toxicology (2012), 50, 250–253
Copyright © 2012 Informa Healthcare USA, Inc.
ISSN: 1556-3650 print / 1556-9519 online
DOI: 10.3109/15563650.2012.670875
       CRITICAL  CARE   
 Received    6    November    2011  ;  accepted    24    February    2012.   
    Address correspondence to Pradeepa Jayawardane, Department 
of Pharmacology, Faculty of Medical Sciences, University of 
Sri Jayewardenepura, Sri Lanka. Tel:       94  71  8019445.  Email: 
pradeepajayawardane@yahoo.co.uk  Copyright © Informa Healthcare USA, Inc. 2012
     Respiratory failure in acute OP poisoning      251
2005 to April 2006 and from Teaching Hospital, Peradeniya 
from May 2006 to December 2006. All patients were 
assessed on admission and repeatedly thereafter for features 
of acute cholinergic syndrome by the fi  rst author and MBBS 
qualifi  ed clinical research assistants. The inclusion criteria 
were admission within 24 hours of ingestion of OP and 
signs of systemic intoxication. Patients under an age of 15 
years and pregnant patients were excluded. Informed writ-
ten consent was obtained from all the study patients. If the 
patients were unconscious, consent was obtained from the 
accompanying relatives, but the consent was confi  rmed with 
the patients themselves when they regained consciousness. 
OP poisoning was confi  rmed by the history from the patient 
and/or relatives, containers brought to hospital, information 
on patient-transfer forms, characteristic smell in the breath, 
and clinical features typical of OP poisoning. OP concen-
tration in plasma was quantifi  ed in 67 of 78 patients using 
reversed phase high performance liquid chromatography 
and ultraviolet detection. Red blood cell acetylcholinest-
erase (RBC AChE) level was assessed in 59 of 78 patients 
using the modifi  ed Ellman method.  9  Accordingly,  additional 
biochemical evidence of OP poisoning (serum OP level or 
RBC AChE level) was available in 69 of the 78 patients. 
As per institutional practises, the patients were treated with 
10  –  15 mg bolus dose of atropine followed by 10  –  15 mg IV 
atropine infusion in 0.9% normal saline over about 12 hours. 
The infusion rate was adjusted according to the patient  ’  s 
clinical situation. If the patient became excessively atropin-
ized, the infusion was discontinued. If the patient developed 
further cholinergic features, further boluses (e.g. 10  –  15 mg 
IV) were given. Pralidoxime was administered 1 g q 6 h by 
slow IV injection for 48 h.   
  Clinical and electrophysiological assessment 
  All the patients were assessed at least twice daily with a 
focused neurological examination to detect signs of IMS 
and at least six times a day for cholinergic (nicotinic and 
muscarinic) signs. Bedside electrophysiological testing 
was carried out by the fi  rst author using a portable Medelec 
Synergy electromyography machine (software version 11). 
The fi  rst assessment was done within 24 hours of poison-
ing in 69 of 78 patients. The studies were repeated daily 
until there were no detectable electrophysiological or clini-
cal abnormalities. Repetitive nerve stimulation (RNS) was 
performed on right and left median and ulnar nerves. Single 
supramaximal stimulation of the same nerves was done to 
detect repetitive responses. Nerves were stimulated super-
fi  cially by a stimulator fi  xed to the respective nerves at the 
wrist. Recordings were done with TECA NCS disposable 
bar electrodes using the belly tendon confi  guration. The 
  “  stimulation  ”   hand was immobilized manually to prevent 
movement artifacts. A 50-Hz notch fi  lter was used. RNS 
studies were done with train of 10 supramaximal stimuli of 
0.1 millisecond at 1, 3, 10, 15, 20, and 30 Hz frequencies. 
There was at least a 15 seconds interval between two trains 
of stimuli. In normal RNS studies, the amplitudes of com-
pound muscle action potentials over the train do not differ. In 
some, at high-frequency stimulations, incremental patterns 
are observed where the amplitude of the compound muscle 
action potentials seems to increase progressively over the 
train. This increment is a normal variant and is described 
as a pseudoincrement. The main abnormalities observed on 
RNS in OP are decrement  –  increment and progressive decre-
ment patterns.  10   The electrophysiological abnormalities of 
the cohort have been described previously.  11  
  Data are presented with conventional nonparametric 
descriptive  summary  statistics.    
 Results 
  All 78 patients had muscarinic and nicotinic symptoms at 
enrolment. Sixty-fi  ve of the 78 patients were males. Fifty-
nine patients had ingested chlorpyrifos. The other patients 
ingested dimethoate (2), phenthoate (1), and diazinon (1) 
and unknown OP (15). 
  Twelve (15%) patients developed respiratory failure 
requiring mechanical ventilation. Early respiratory failure 
(within 24 hours) was associated with a lower Glasgow Coma 
Scale (GCS) and a shorter duration of ventilation compared 
to those developing respiratory failure later (Table 1). 
  Seven of the 12 developed respiratory failure within 24 
hours when they were acutely ill in severe cholinergic crisis 
(early respiratory failure). The important clinical features at 
the time of intubation of these seven patients are described 
in Table 1. Five patients developed respiratory failure more 
than 24 hours after OP ingestion (late respiratory failure). 
None of the patients had a GCS at the time of intubation 
of less than 12, indicating central nervous system (CNS) 
depression was not a major factor in the respiratory depres-
sion. All fi  ve patients had severe muscle weakness (Medical 
Research Council grade 3 or less) involving the proximal 
limb muscles and neck fl  exors with weakness of the muscles 
supplied by the motor cranial nerves confi  rming IMS. One 
of these patients died when she was still in respiratory failure 
9 days following admission. Features of those fi  ve patients at 
the time of intubation are described in Table 1. 
  Frequent electrophysiological studies were performed 
from admission in all 12 patients to monitor neuromuscular 
transmission. The patients who developed early respiratory 
failure had no electrophysiological evidence of neuromuscular 
transmission failure around the time of intubation. However, 
three of the seven developed a mild degree of weakness and 
decrement – increment  patterns  at  high frequency stimulations 
after 24 hours as seen in the   “  forme fruste  ”   IMS.  11  
  All patients who developed respiratory failure after the fi  rst 
24 hours demonstrated electrophysiological abnormalities of 
progressive neuromuscular transmission failure,  10,11  and at the 
time of intubation they had severe decrement or progressive 
decrement patterns at high frequency stimulations (20  –  30 Hz) 
suggesting severe disruption of neuromuscular transmission.    
 Discussion 
  The mechanisms of respiratory failure following acute OP 
poisoning are complex. Many patients develop respiratory Clinical Toxicology vol. 50 no. 4 2012
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failure in the early stage of severe acute poisoning. In 1987, 
Senanayake and Karalliedde described a group of patients 
who developed respiratory failure between 1 and 4 days after 
poisoning when they were otherwise relatively stable and 
free of muscarinic signs and coined the term   “  intermediate 
syndrome ”   (IMS). 6   This syndrome overlapped extensively 
with the   “  Type II paralysis  ”   described in 1974 by Wadia.  7,12  
Wadia also referred to   “  Type I paralysis  ”  , early weakness 
with pyramidal signs, miosis, and impaired consciousness. 
Both papers described the electrophysiological signs associ-
ated with IMS/Type II paralysis. We also found these in our 
late respiratory failure group: sequential electrophysiological 
abnormalities indicating progressive neuromuscular transmis-
sion failure. Patients initially developed decrement  – 
increment patterns at high-frequency stimulations. With 
clinical deterioration, decrement  –  increment patterns were 
progressively observed at intermediate and low frequencies, 
and at high frequencies a combination of decrement  –  incre-
ment and repetitive fade pattern was observed. Progressive 
decrement patterns were observed in patients who were 
ventilated for respiratory paralysis. The degree of muscle 
weakness correlated well with the electrophysiological 
features during clinical progression of IMS.  11  
  In this study, for the fi  rst time, we describe the electro-
physiological correlates of early respiratory failure in OP 
poisoning. This showed that the early respiratory failure is 
not associated with the same neuromuscular transmission 
defects seen in IMS. 
  None of these abnormalities was observed in those who 
developed early respiratory failure. This strongly suggests 
that this early respiratory failure does not involve neuromus-
cular transmission failure. The patients who developed early 
respiratory failure had relatively severe muscarinic features 
and also usually a low GCS suggesting CNS involvement 
and fi  tted the description of patients Wadia et     al.  12   referred 
to as having   “  Type I paralysis  ”  . They stated this was a mus-
carinic/CNS toxic syndrome and it may well be that they 
observed the lack of electrophysiological fi  ndings in early 
respiratory failure but only documented the positive fi  ndings 
in their reports. 
  This study provides support for the conclusions from 
the animal studies of Bird et     al.  13   and the speculations of 
earlier studies of respiratory failure in humans  7,5   that early 
respiratory failure is primarily due to CNS and muscarinic 
effects. The study reiterates the importance of early and 
rapid titration of anti-muscarinic agents such as atropine.  14  
There is also a need for investigation of other antidotes, 
which may be more effective in the CNS as all these 
patients developed respiratory failure in spite of receiving 
atropine. There is also a need for antidotes, which protect 
the pre- and post-synaptic molecular targets of OP in the 
neuromuscular junction that underlie late respiratory fail-
ure. While RNS features may be an appropriate surrogate 
outcome for such studies, a validated means to measure 
muscarinic and CNS related respiratory dysfunction is 
needed to facilitate the development of better antidotes for 
the early syndrome. 
  Our study had some limitations. The number of patients 
who developed respiratory failure was small, presumably 
because of improved care. Chlorpyrifos was the OP agent 
in the majority and other different types of OPs are not 
adequately represented in this study. Since it is believed that 
different OPs differ in their clinical profi  le and response 
to oximes  15   the frequency, time-course and manifestations 
of early and late respiratory failure may vary accordingly. 
Although to some extent this was an advantage in seeing two 
clearly distinct patterns. 
  RNS studies were performed only on distal muscles 
although the diaphragm may be more indicative of the 
underlying pathophysiology. However, these RNS fi  ndings 
did correlate reasonably well with features of IMS in our 
series. Phrenic nerve conduction studies are not frequently 
done because the technique is less precise and standard-
ized than peripheral nerve conduction studies, and they are 
   Table  1 .  Characteristics of patients developed early respiratory failure and late respiratory failure.   
Early respiratory failure 
(median and range)   n       7
Late respiratory failure 
(median and range)   n       5
Age  (years) 22  (18 – 56) 25  (18 – 29)
Male:female 5:2 2:3
Type of OP 5 Chlorpyrifos 1 Chlorpyrifos
1 Phenthoate 1 Dimethoate
1 Unknown 3 Unknown
Time since ingestion to 
intubation (hours)
6  (2 – 17) 86  (24 – 95)
Admission
GCS 11  (3 – 15) 15  (9 – 15)
SBP  (mmHg) 120  (90 – 140) 117  (110 – 140)
Pulse  (BPM) 60  (60 – 92) 80  (60 – 120)
On intubation
GCS 10  (4 – 13) 15  (12 – 15)
SBP  (mmHg) 120  (90 – 130) 100  (100 – 130)
Pulse  (BPM) 110  (72 – 120) 76  (60 – 120)
Duration  of  ventilation  (hours) 99  (2 – 203) 208  (93 – 718)
      OP, organophosphate; GCS, Glasgow Coma Scale; SBP, systolic blood pressure; BPM, beats per minute.     Copyright © Informa Healthcare USA, Inc. 2012
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more diffi  cult to conduct. The technique has recently been 
revised by Bolton and colleagues  16   with promising results. 
They measured the reproducibility of the diaphragm com-
pound action potential after electrical stimulation of the 
phrenic nerve and found it had the same accuracy as the 
thenar compound action potential after electrical stimula-
tion of the median nerve.  16   Phrenic nerve conduction stud-
ies have been conducted in OP poisoned patients with late 
respiratory failure by Singh et     al.  17   They did not do con-
current RNS studies, so it is not clear whether the phrenic 
nerve conduction studies were better than peripheral RNS 
studies in following the pathophysiology. Ideally, to study 
the diaphragmatic neuromuscular junction, serial phrenic 
nerve RNS studies would need to be performed in acutely 
poisoned patients. This has not been done before and may 
not be practical.     
 Conclusions 
  The normal RNS in all seven patients who developed early 
respiratory failure suggests that the mechanism is muscarinic 
and/or central and not due to neuromuscular junction failure. 
This re-emphasizes the need for early rapid atropinisation. 
Further studies are needed to quantify CNS and muscarinic 
dysfunction to assist in the development of better treatments 
for the severe and early OP poisoning.     
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